5-氨基酮戊酸光动力疗法联合重组人干扰素α-2b凝胶预防尖锐湿疣复发疗效观察

目的：观察5-氨基酮戊酸光动力疗法联合重组人干扰素α-2b凝胶治疗尖锐湿疣的临床疗效。方法40例尖锐湿疣患者随机分为治疗组和对照组,治疗组20例行5-氨基酮戊酸光动力疗法联合重组人干扰素α-2b凝胶,对照组20例行5-氨基酮戊酸光动力疗法。治疗后每2周复查1次,随访6个月,观察两组的疗效和复发情况。结果治疗组治愈率90%,对照组治愈率50%。两组疗效比较差异有统计学意义（P＜0.05）,治疗组随访复发率明显低于对照组（P＜0.05）。结论5-氨基酮戊酸光动力疗法联合重组人干扰素α-2b凝胶治疗尖锐湿疣是一种安全有效、预防复发的新疗法。     

5-氨基酮戊酸光动力疗法联合液氮冷冻治疗肛周尖锐湿疣疗效观察

目的:探讨5-氨基酮戊酸光动力联合液氮冷冻治疗肛周尖锐湿疣的临床疗效。方法:60例肛周尖锐湿疣患者随机分为对照组和观察组,两组均采用5-氨基酮戊酸光动力治疗,观察组在此基础上加用液氮冷冻治疗。结果:观察组治愈率明显高于对照组,复发率明显低于对照组(P0.027)。结论:5-氨基酮戊酸光动力联合液氮冷冻治疗肛周尖锐湿疣能明显提高疗效,并有效预防尖锐湿疣复发。     

5-氨基酮戊酸光动力对男性尿道口尖锐湿疣临床疗效研究

目的:观察5-氨基酮戊酸光动力疗法治疗男性尿道口尖锐湿疣的临床疗效.方法:选取我院于2014年3月~2016年3月收治的男性尿道口尖锐湿疣患者56例,采用回顾性分析法分为观察组和对照组,每组28例,其中观察组采用将5-氨基酮戊酸浸湿的无菌脱脂棉敷于尿道口联合激光照射治疗的方法;对照组采用二氧化碳激光治疗的方法,比较两组临床治疗效果.结果:治疗后,观察组的总有效率为92.86%,明显高于对照组的78.57%,差异显著(P<0.05).结论:采用光动力配合5-氨基酮戊酸治疗男性尿道口尖锐湿疣总有效率高达92.86%,安全,可广泛应用于临床.     

5-氨基酮戊酸光动力疗法降低湿疣复发的应用

目的应用5-氨基酮戊酸光动力疗法治疗湿疣,从而降低其复发率并观察其应用效果。方法对比分析法是将单用电离子治疗仪对湿疣进行预防与治疗的方法与电离子治疗仪联合5-氨基酮戊酸光动力疗法对湿疣进行治疗与预防的方法之间的效果比较。本文采用这种方法对本院自2011年1月至2013年1月收治的120例病患进行临床治疗,采用随机分组法将其分为治疗组与对照组,每组患者各60例,观察两组疗程结束后尖锐湿疣降低复发率的差异。结果治疗组对于降低湿疣复发的有效性明显要比对照组要高,两组数据比较存在差异性,具有统计学意义。结论氨基酮戊酸光动力疗法对于降低湿疣复发具有良好的预防效果,缓解了患者痛苦,具有经济与医学价值。     

5-氨基酮戊酸-光动力疗法治疗复发性尖锐湿疣76例观察

观察5-氨基酮戊酸-光动力疗法(ALA-PDT)治疗复发性尖锐湿疣的疗效和复发率。回顾性分析76例尖锐湿疣采用ALA-PDT治疗的结果。76例中,43例皮损＜1 cm者经1～3次治疗后无一例复发;33例皮损1～5 cm者经2～6次治疗后,有2例复发,复发率为6.10%,经再次治疗痊愈,总治愈率100%。ALA-PDT治疗复发性尖锐湿疣的疗效确切,对人体皮肤无毒副作用,安全易操作,复发率低,临床疗效好。     

非手术综合治疗巨大型尖锐湿疣13例疗效观察

目的 观察钬激光联合光动力及冷冻综合治疗巨大型尖锐湿疣的疗效和安全性.方法 13例肛周、外生殖器巨大型尖锐湿疣患者,男8例、女5例,通过钬激光消融疣体,清理创面干净后,立即给予氨基酮戊酸光动力治疗,复发后给予光动力或冷冻治疗,共治疗1～8次.结果 13例巨大疣体均经钬激光消融1次清除,随后进行的光动力治疗中,1次治疗即痊愈者4例;余9例经过2～3次的光动力结合冷冻治疗中获得痊愈;随访3～6月未复发.不良反应主要是术中疼痛不适和术后瘢痕及色素改变.结论 钬激光联合光动力及冷冻非手术综合治疗对巨大型尖锐湿疣安全、有效.     

光动力疗法联合咪喹莫特治疗尖锐湿疣观察

目的观察5-氨基酮戊酸光动力疗法（ALA-PDT）联合咪喹莫特乳膏治疗尖锐湿疣的疗效和安全性。方法试验组48例患者采用ALA-PDT治疗3次,后继续外用咪喹莫特乳膏,每周3次,共8周。对照组46例患者采用ALA-PDT治疗3次。ALA-PDT治疗后随访12周。结果试验组患者痊愈率为87.5%（42/48）,复发率为4.8%（2/42）;对照组患者痊愈率为65.2%（30/46）,复发率为16.7%（5/30）。两组患者痊愈率比较差异有统计学意义（P〈0.05）,复发率比较差异无统计学意义（P〉0.05）。试验组不良反应主要为局部较轻的疼痛、红斑、灼热、糜烂等。结论 5-氨基酮戊酸光动力疗法联合咪喹莫特乳膏治疗尖锐湿疣疗效好,复发率低,不良反应轻。     

艾拉光动力疗法联合丹参酮胶囊治疗中度痤疮的疗效观察

目的 探讨5-氨基酮戊酸凝胶(商品名:艾拉)-光动力疗法(ALA-PDT)联合丹参酮胶囊治疗中度痤疮的有效性与安全性.方法 选择2015年6月至2017年1月期间惠州市皮肤病防治研究所皮肤科收治的中度痤疮患者133例,并随机分为3组,对照A组41例给予丹参酮胶囊治疗,对照B组46例给予5-氨基酮戊酸光动力疗法(ALA-PDT)治疗,观察组46例给予5-氨基酮戊酸光动力疗法(ALA-PDT)联合丹参酮胶囊治疗.比较3组的临床效果.结果 治疗4周后,观察组总有效率为 84.78％,显著高于对照A组的36.59％及对照B组的56.52％(x2=21.389 4、8.859 3,P＜0.05),对照B组总有效率56,52％明显高于对照A组的36.59％(x2=3.457 9,P＜0.05).结论 艾拉光动力疗法联合丹参酮胶囊治疗中度痤疮具有较好的疗效,损伤小,恢复时间短,安全性高,为基层医院提供了一种安全、有效、理想的治疗方法,值得临床推广.     

5-氨基酮戊酸联合电离子治疗宫颈尖锐湿疣的疗效观察

目的：观察5--氨基酮戊酸光动力疗法（ALA-PDT）联合电离子治疗宫颈尖锐湿疣的临床疗效。方法将62例宫颈尖锐湿疣患者随机分为治疗组和对照组,二组均为31例。治疗组采用ALA-PDT联合电离子治疗,对照组仅用电离子治疗,比较两者的疗效和复发率。结果治疗组的治愈率为90.3%,复发率为9.7%;对照组治愈率及复发率分别为64.5%、35.5%,两组比较差异有统计学意义（P＜0.05）。结论 ALA-PDT联合电离子治疗宫颈尖锐湿疣效果显著,值得推广。     

20%5-氨基酮戊酸光动力联合液氮冷冻治疗尖锐湿疣

目的探讨20%5-氨基酮戊酸光动力联合液氮冷冻治疗尖锐湿疣的疗效和安全性,并分析尖锐湿疣患者人类乳头瘤病毒(HPV)基因型感染分布情况。方法尖锐湿疣患者108例随机分为两组,治疗组56例,对照组52例。治疗组患者采用20%5-氨基酮戊酸光动力联合液氮冷冻治疗,每周1次,连续3次。对照组先外用0.5%鬼臼毒素酊,再根据皮肤情况选择CO2激光或冷冻治疗,连续治疗3周。两组治疗结束后均随访6个月。两组患者在治疗前后均使用PCR膜杂交法检测21种HPV基因型分布情况,并对检测结果进行分析。结果治疗组与对照组3次治疗后的疣体清除率分别为97.1%和78.4%,治愈率分别为96.4%和76.9%,组间比较均具有显著差异(P<0.01);两组复发率和不良反应发生率比较亦有显著差异(P<0.01、P<0.05)。HPV基因型检测结果:108例尖锐湿疣患者共检出16种基因型,治疗组的HPV清除率明显优于对照组,尤其是针对伴有高、中危型和混合型感染时疗效更为显著(P<0.01)。结论 20%5-氨基酮戊酸光动力联合液氮冷冻治疗尖锐湿疣疗效显著,疣体清除率及临床治愈率高,复发率低,不良反应轻微,在尖锐湿疣治疗中尤其是对伴有高危型HPV及混合型感染患者值得临床进一步广泛推广应用。     

5-氨基酮戊酸光动力治疗尖锐湿疣60例的临床观察

目的观察5-氨基酮戊酸光动力疗法（ALA—PDT）治疗尖锐湿疣的疗效。方法（1）将确诊为尖锐湿疣病例人选,并按每个病例总的光照次数由2—5次分为4组。（2）20％5-氨基酮戊酸溶液湿敷于皮损或疣体上,覆盖面积约超出皮损边缘1．0cm范围。持续湿敷3h,外加封包。（3）特定波长激光照射：用波长为635nm的光动力治疗仪照射,每次照射剂量为100J／cm^2。每间隔时间1—2周照一次,根据病情需要照2-5次不等。（4）随访6个月,观察疗效。结果4组患者经过ALA—PDT治疗后均能清除疣体。至6个月随访结束时,2次照射组复发率28．57％;3次照射组复发率14．28％;4次照射组复发率12．50％;5次照射组复发率12．50％。结论ALA—PDT治疗尖锐湿疣均能取得满意的治疗效果,ALA—PDT治疗尖锐湿疣次数不应少于3次,如无特殊情况,亦无须增加治疗照射次数的必要,以免增加患者经济负担。     

5-氨基酮戊酸光动力疗法联合电灼术治疗肛周尖锐湿疣疗效观察

目的 评价5-氨基酮戊酸光动力疗法（ALA-PDT）联合电灼术治疗肛周尖锐湿疣的疗效和复发率.方法 将67例肛周尖锐湿疣患者按门诊就诊顺序随机分为三组,联合治疗组22例用电灼术去除显性疣体后立即进行ALA-PDT治疗,每周1次,连续治疗3～4次;光动力组22例,用ALA-PDT治疗,每周1次,1个月为1个疗程;电灼术组23例,用传统方法电灼术对所有皮损逐个进行电灼气化治疗,每周1次的分批治疗,1个月为1个疗程.末次治疗后随访6个月判定疗效及观察复发率.结果 联合治疗组痊愈率为90.9％（20/22）,复发率为9.1％ （2/22）;光动力组痊愈率为54.5％ （12/22）,复发率为22.7％ （5/22）;电灼术组痊愈率为39.1％ （9/23）,复发率为43.5％ （10/23）.联合治疗组的痊愈率和复发率与电灼术治疗组差异有统计学意义（P =0.000;P =0.017）.结论 ALA-PDT治疗肛周尖锐湿疣治愈率高,复发率低,副作用小.     

A New Bicoumarin from Stellera Chamaejasme L

Thirteen compounds were isolated from roots of Stellera chamaejasme L. (Thymelaeaceae). They are β-sitosterol (2), simplexin (3), pimelea factor P2 (4), daucosterol (5), (+)-3-hydroxy-1,5-diphenyl-1-pentanone (6), 4-ethoxy-benzoic acid (7), 2,4,6-Trimethoxy-benzoic acid (8), (+)-afzelechin (9), fumaric acid (10), N,N-dimethyl-L-aspartic acid (11), umbelliferone (12), daphniretin (13) and a novel bicoumarin named bicoumastechamin (1). Among the known compounds, 7, 8, 9, 10 and 11 were first isolated from this plant, and 6 was first isolated from the natural resources. Their structures have been elucidated on the basis of spectral data. In vitro bioassays showed that 4 inhibited cancer cell growth, 13 exhibited immunomodulatory activity, and 6 exhibited both immunomodulatory and anti-tumor activity.     

Lignans from Kadsura angustifolia

A new dibenzocyclooctadiene lignan named angustifolin D (1) together with four known lignans: kadsulignan L (2), kadsulignan N (3), schisantherin P (4) and meso-dihydroguaiaretic acid (5) were isolated from the stems of Kadsura angustifolia. Their structures and stereochemistries were elucidated by spectral studies. Compounds 2 and 5 showed moderate plateletactivating factor (PAF) antagonistic activities with IC₅₀ values of 2.6 × 10^-5 and 4.1 × 10^-5 M, respectively.     

Triterpenes from Tripterygium wilfordii Hook

Two new friedelane-type triterpenes, tripterfrielanons A (1) and B (2), along with six known triterpenoids, friedelin (3), canophyllal (4), canophyllalic acid (5), 3-oxo-29-hydroxyfriedelane (6), wilforlide A (7), wilforlide B (8), have been isolated from the EtOH extract of the roots of Tripterygium wilfordii Hook.f. Compounds 4, 5, 6 were isolated for the first time from this plant. The new triterpenes 1 and 2 exhibited mild cytotoxic activity against human Hela cell lines in vitro. The assay showed the IC₅₀ of 1 and 2 were 8.5 and 25 μg/mL, respectively.     

Laser-mediated photodynamic therapy of actinic cheilitis

Actinic cheilitis (AC) is a common precancerous condition for which a safe, effective, rapid, and cosmetically favorable treatment is needed. The objective of this study was to assess the safety and efficacy of the long-pulsed pulsed dye laser (LP PDL) (595 nm) with photodynamic therapy (PDT) for the treatment of AC. This study was designed to be a prospective, proof-of concept pilot study to assess safety and efficacy of LP PDL in conjunction with topical 20% 5-aminolevulinic acid solution PDT for the treatment of AC. Control patients received LP PDL alone. The setting was an outpatient clinical research center. A volunteer sample of 21 patients with biopsy-proven AC was enrolled (age range, 42-86 years; skin types I-III). All patients were refractory to prior therapies. Patients with a history of herpes labialis were pre-treated with famcyclovir. Nineteen patients received one-to-three treatments of topical 20% 5-aminolevulinic acid for 2-3 hours, followed by LP PDL (595 nm) at monthly intervals. Two control patients received one treatment with LP PDL alone. Patients in the ALA-LP PDL group were followed at 1, 2, 3, 6, 9, and 12 months. Clearance of AC was assessed by clinical evaluation. Control patients were followed to the one month interval. We observed none-to-mild pain; slight-to-moderate erythema; no crusting, purpura, or scarring; treatment time of less than one minute; and complete resolution of post-operative erythema by day three. Complete clearance was achieved in 13/19 (68%) of patients following a mean of 1.8 treatments (7/13 (37%) after one, 2/13 (11%) after two, and 1/13 (21%) after three treatments). Patients were followed for a mean of 4.1 (range 1-12) months. Among the remaining cases, partial clearing was achieved in two patients, recurrence during the follow-up interval was observed in one patient, and failure to follow-up occurred in three patients. Post-operative impetiginization occurred in three patients with erosive AC, which resolved with dicloxacillin therapy. Among the control patients, no clearing was observed. Treatment of AC using LP PDL (595 nm) at nonpurpuric parameters following topical application of 5-aminolevulinic acid at short incubation times is safe and effective. It may offer the advantages of rapid incubation, treatment, and recovery times, minimal discomfort, excellent cosmetic outcome, and good efficacy rates. Patients with erosive AC should receive antibacterial prophylaxis. Multiple treatments may be required for complete clearing.     

Anthraquinones from Gladiolus gandavensis

Five new anthraquinones have been obtained from the ethanolic extracts of the subterranean corms of Gladiolus gandavensis Van Houtt. Their structures were elucidated as 3,8-dihydroxy-6-methoxy-1-methyl-anthraquinone (gandavensin D, 1), methyl 3,8-dihydroxy-6,7-methylenedioxy-1-methyl-anthraquinone- 2-carboxylate (gandavensin E, 2), 2,3,8-trihydroxy-6-methoxy-1-methoxymethyl-anthraquinone (gandavensin F, 3), 8-hydroxy-3,6-dimethoxy-1-methyl-anthraquinone-2-carboxylic acid (gandavensin G, 4) and 1,7-dihydroxy-3,6-dimethoxy-anthraquinone (gandavensin H, 5) on the basis of spectral data. The known compounds isolated for the first time from this plant have been determined to be methyl 3,6,8-trihydroxy-7-methoxy-1-methyl-anthraquinone-2-carboxylate (6), methyl 3,6,8-trihydroxy-1-methyl-anthraquinone-2-carboxylate (7), 3,8-dihydroxy-6-methoxy-1-methyl-anthraquinone-2-carboxylic acid (8), 3,6,8-trihydroxy-1-methyl-anthraquinone-2-carboxylic acid (9), 6,8-dihydroxy-3-methoxy-1-methyl-anthraquinone-2-carboxylic acid (10), methyl 3,8-dihydroxy-6-methoxy-1-methyl-anthraquinone-2-carboxylate (11) and methyl 3,7,8-trihydroxy-1-methyl-anthraquinone-2-carboxylate (12).     

ent-Kaurenoids from the roots of Cacalia pilgeriana

Two new ent-kaurenoids,19-acetoxyl-ent-3β,17-dihydroxykaur-15-ene (1), 19-acetoxyl-ent-3β-hydroxykaur-15-en-17-al (2), together with seven known ent-kaurenoids: ent-kaur-16-en-19-al (3), ent-kaur-16-en-19-oic acid (4), ent-kauran-16β,17-diol (5), ent-15β, 16β-epoxy-17-hydroxykauran-19-oic acid (6),19-acetyl-ent-3β-hydroxyl-kaur-16-ene (7), ent-3β,19-dihydroxykaur-16-ene (8), ent-17-hydroxykaur-15-ene (9), were isolated from Cacalia pilgeriana. Their structures were elucidated by spectroscopic methods including 2D NMR spectral analysis.     

Ether-soluble resin glycosides from the roots of Ipomoea batatas

Two new resin glycosides, batataosides I (1) and II (2), and five known compounds, friedelin (3), scopoletin (4), octadecyl caffeate (5), β-sistosterol (6) and daucosterol (7), were isolated from the roots of Ipomoea batatas. Their structures have been determined based on the chemical and spectral data. Batataosides I and II have novel structures because the core simonic acid B was esterised with cinnamic acid for the first time, and three different substituent esterification groups in one resin glycoside is scarce. The absolute configuration of the aglycone was elucidated to be S by Mosher's method.